other_material
confidence high
sentiment positive
materiality 0.55
Genprex gets US and EU patent allowances for REQORSA combo with PD-L1/PD-1 antibodies; trial underway
Genprex, Inc.
- USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.
- Korea granted patent for REQORSA + PD-L1 antibodies; Genprex pursuing additional patents in Europe, Canada, Brazil, China, Israel for Acclaim-3 trial.
- Patents for REQORSA + PD-1 antibodies already granted in US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.
- Acclaim-3 Phase 1/2 trial testing REQORSA + Tecentriq maintenance in ES-SCLC has FDA Fast Track and Orphan Drug Designation.
item 8.01item 9.01